Matinas BioPharma rises on research pact with ViiV Healthcare

Matinas BioPharma Holdings

15/05/2019 14:05

** Drug developer's U.S.-listed shares  MTNB.N  rise 15 pct
to $1.1 premarket
    ** Co says it has tied up with ViiV Healthcare to evaluate
the use of MTNB's lipid nano-crystal (LNC) drug delivery
technology  urn:newsml:reuters.com:*:nGNX69PGKj
    ** ViiV Healthcare is a company established by Pfizer Inc
 PFE.N  and GlaxoSmithKline Plc  GSK.L , focused on developing
treatments for HIV 
    ** Co says under the pact, select antiviral treatments will
be developed using Matinas' LNC delivery technology
    ** Says a lead LNC-antiviral treatment will be identified to
take forward in development
    ** Last year, MTNB announced a research collaboration with
the National Institutes of Health (NIH) for the development of a
new therapy for HIV, using its LNC technology  urn:newsml:reuters.com:*:nFWN1U50JZ
    ** Up to Tuesday's close, MTNB had surged ~60 pct YTD

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((Reuters Messaging:
manojna.kalyani.thomsonreuters.com@reuters.net))